MX370412B - Compuesto antimicotico. - Google Patents

Compuesto antimicotico.

Info

Publication number
MX370412B
MX370412B MX2017007188A MX2017007188A MX370412B MX 370412 B MX370412 B MX 370412B MX 2017007188 A MX2017007188 A MX 2017007188A MX 2017007188 A MX2017007188 A MX 2017007188A MX 370412 B MX370412 B MX 370412B
Authority
MX
Mexico
Prior art keywords
antimycotic compound
compound
antimycotic
mycoses
therapy
Prior art date
Application number
MX2017007188A
Other languages
English (en)
Spanish (es)
Other versions
MX2017007188A (es
Inventor
Mihiro Sunose
Kazuhiro Ito
Rapeport Garth
Christopher COLLEY Thomas
Original Assignee
Pulmocide Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pulmocide Ltd filed Critical Pulmocide Ltd
Publication of MX2017007188A publication Critical patent/MX2017007188A/es
Publication of MX370412B publication Critical patent/MX370412B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • GPHYSICS
    • G06COMPUTING OR CALCULATING; COUNTING
    • G06FELECTRIC DIGITAL DATA PROCESSING
    • G06F1/00Details not covered by groups G06F3/00 - G06F13/00 and G06F21/00
    • G06F1/26Power supply means, e.g. regulation thereof
    • G06F1/32Means for saving power
    • G06F1/3203Power management, i.e. event-based initiation of a power-saving mode
    • G06F1/3234Power saving characterised by the action undertaken
    • G06F1/325Power saving in peripheral device
    • G06F1/3268Power saving in hard disk drive
    • GPHYSICS
    • G11INFORMATION STORAGE
    • G11CSTATIC STORES
    • G11C11/00Digital stores characterised by the use of particular electric or magnetic storage elements; Storage elements therefor
    • G11C11/21Digital stores characterised by the use of particular electric or magnetic storage elements; Storage elements therefor using electric elements
    • G11C11/34Digital stores characterised by the use of particular electric or magnetic storage elements; Storage elements therefor using electric elements using semiconductor devices
    • G11C11/40Digital stores characterised by the use of particular electric or magnetic storage elements; Storage elements therefor using electric elements using semiconductor devices using transistors
    • G11C11/401Digital stores characterised by the use of particular electric or magnetic storage elements; Storage elements therefor using electric elements using semiconductor devices using transistors forming cells needing refreshing or charge regeneration, i.e. dynamic cells
    • G11C11/4063Auxiliary circuits, e.g. for addressing, decoding, driving, writing, sensing or timing
    • G11C11/407Auxiliary circuits, e.g. for addressing, decoding, driving, writing, sensing or timing for memory cells of the field-effect type
    • G11C11/4074Power supply or voltage generation circuits, e.g. bias voltage generators, substrate voltage generators, back-up power, power control circuits

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Theoretical Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microelectronics & Electronic Packaging (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Computer Hardware Design (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2017007188A 2014-12-05 2015-12-04 Compuesto antimicotico. MX370412B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14196662 2014-12-05
PCT/GB2015/053731 WO2016087878A1 (en) 2014-12-05 2015-12-04 Antimycotic compound

Publications (2)

Publication Number Publication Date
MX2017007188A MX2017007188A (es) 2017-08-28
MX370412B true MX370412B (es) 2019-12-11

Family

ID=52006914

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017007188A MX370412B (es) 2014-12-05 2015-12-04 Compuesto antimicotico.

Country Status (18)

Country Link
US (12) US10106531B2 (enExample)
EP (2) EP3227277B1 (enExample)
JP (2) JP6666345B2 (enExample)
KR (1) KR102579848B1 (enExample)
CN (2) CN107001343B (enExample)
AU (1) AU2015356795B2 (enExample)
BR (1) BR112017008481B1 (enExample)
CA (1) CA2963625C (enExample)
DK (2) DK3227277T3 (enExample)
EA (1) EA033736B1 (enExample)
ES (2) ES2790875T3 (enExample)
HU (2) HUE048905T2 (enExample)
IL (1) IL251631B (enExample)
MX (1) MX370412B (enExample)
PL (1) PL3227277T3 (enExample)
PT (1) PT3227277T (enExample)
SG (1) SG11201702835RA (enExample)
WO (2) WO2016087880A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE048905T2 (hu) 2014-12-05 2020-08-28 Pulmocide Ltd Antimikotikus vegyület
JP6694886B2 (ja) 2014-12-18 2020-05-20 プルモシデ リミテド 4,5−ジヒドロ−6H−チエノ[3,2−d]ベンゾアゼピン誘導体及び呼吸器合胞体ウイルス(RSV)感染を治療するためのその使用
JP6811727B2 (ja) 2015-05-21 2021-01-20 プルモシデ リミテド 抗真菌性の4−(4−(4−(((3r,5r)−5−((1h−1,2,4−トリアゾール−1−イル)メチル)−5−(2,4−ジフルオロフェニル)テトラヒドロフラン−3−イル)メトキシ)−3−メチルフェニル)ピペラジン−1−イル)−n−(2−ヒドロキシシクロヘキシル)ベンズアミド、又はその医薬として許容し得る塩
WO2017093491A1 (en) * 2015-12-04 2017-06-08 Pulmocide Limited Antimycotic triazole compound
WO2018096405A1 (en) * 2016-11-28 2018-05-31 Cellix Bio Private Limited Compositions and methods for the treatment of oral infectious diseases
WO2018115319A2 (en) 2016-12-23 2018-06-28 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Inhibitors of cytochrome p450 family 7 subfamily b member 1 (cyp7b1) for use in treating diseases
GB201917867D0 (en) * 2019-12-06 2020-01-22 Pulmocide Ltd Polymorphs
EP3858357A1 (en) * 2020-01-28 2021-08-04 Diaccurate Use of azole compounds to stimulate the immune system and as inhibitors for s-pla2gib
RU2770598C1 (ru) * 2021-06-29 2022-04-18 Федеральное государственное автономное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" (ПГНИУ) ПРИМЕНЕНИЕ ПРОТИВОГРИБКОВОГО СРЕДСТВА НА ОСНОВЕ 2-((4-R1-5-R2-3-(ЭТОКСИКАРБОНИЛ)ТИОФЕН-2-ИЛ)АМИНО)-4-ОКСО-4-R3-БУТ-2-ЕНОВЫХ КИСЛОТ ПО ОТНОШЕНИЮ К Candida aldicans
WO2025114603A1 (en) 2023-11-30 2025-06-05 Basilea Pharmaceutica International Ag, Allschwil Pharmaceutical combinations for use in the treatment of fungal infections

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5533466A (en) * 1978-07-14 1980-03-08 Janssen Pharmaceutica Nv Novel azole derivatives and their manufacture
CH655103A5 (de) * 1983-03-11 1986-03-27 Sandoz Ag Azolderivate, verfahren zu ihrer herstellung und ihre verwendung.
CA1292472C (en) 1985-12-03 1991-11-26 Alfonsus Guilielmus Knaeps Derivatives of ¬¬4-¬4-(4-phenyl-1-piperazinyl)- phenoxymethyl|-1,3-dioxolan-2-yl|methyl|-1h-imidazoles and 1h-1,2,4-triazoles
DE3609598A1 (de) * 1986-03-21 1987-10-01 Hoechst Ag 2-azolylmethyl-2-aryl-1,3-dioxolane und deren salze, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung
JPH0717634B2 (ja) 1987-11-20 1995-03-01 シェリング・コーポレーション トリ‐およびテトラ‐置換‐オキセタンおよびテトラヒドロフランおよびその中間体
US5039678A (en) 1989-03-23 1991-08-13 Wake Forest University Method of increasing cranial vessel proliferation by administering nimodipine
US5039676A (en) 1990-05-11 1991-08-13 Schering Corporation Tri- and tetra-substituted-oxetanes and tetrahydrofurans and intermediates thereof
US5403937A (en) * 1993-04-30 1995-04-04 Schering Corporation Process for preparing intermediates for the synthesis of antifungal agents
US5714490A (en) 1993-12-21 1998-02-03 Schering Corporation Tetrahydrofuran antifungals
AU681753B2 (en) 1993-12-21 1997-09-04 Merck Sharp & Dohme Corp. Tetrahydrofuran antifungals
US5486625A (en) 1994-07-08 1996-01-23 Schering Corporation Process for the preparation of chiral intermediates useful for the synthesis of antifungal agents
IL118464A (en) 1995-06-02 2000-08-13 Schering Corp (2R-cis)-4-¬4-¬4-¬4¬¬-5-(2',4 dihalophenyl)-tetrahydro-5-(1-H-1,2,4,triazol-1-yl-methyl)furan-3-yl(methoxy¾phenyl¾-1-piperazinyl¬phenyl2,4,dihydro2¬(5)-1-ethyl-2-(5)hydroxy propyl¾-3H-1,2,4-triazol-3-one and pharmaceutical compositions comprising them
EP0957101A1 (en) 1998-05-14 1999-11-17 Janssen Pharmaceutica N.V. Water soluble azoles as broad-spectrum antifungals
EP2090165A3 (en) 2001-04-03 2012-03-28 Schering Corporation Antifungal composition with enhanced bioavailability
CA2709784A1 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
US8324385B2 (en) * 2008-10-30 2012-12-04 Madrigal Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
ES2649995T3 (es) * 2011-07-18 2018-01-16 Merck Patent Gmbh Benzamidas
WO2013036866A1 (en) 2011-09-07 2013-03-14 The Johns Hopkins University Itraconazole analogs and use thereof
HUE048905T2 (hu) 2014-12-05 2020-08-28 Pulmocide Ltd Antimikotikus vegyület
GB201917867D0 (en) 2019-12-06 2020-01-22 Pulmocide Ltd Polymorphs

Also Published As

Publication number Publication date
WO2016087878A1 (en) 2016-06-09
JP6669751B2 (ja) 2020-03-18
US11008307B2 (en) 2021-05-18
US20190023697A1 (en) 2019-01-24
US20200239453A1 (en) 2020-07-30
DK3227277T3 (da) 2020-04-27
US10487073B2 (en) 2019-11-26
US11661415B2 (en) 2023-05-30
US20200002320A1 (en) 2020-01-02
BR112017008481B1 (pt) 2022-09-06
US20170320858A1 (en) 2017-11-09
US20200399253A1 (en) 2020-12-24
IL251631A0 (en) 2017-06-29
CN112375073A (zh) 2021-02-19
CN107001343B (zh) 2020-12-11
US10800762B2 (en) 2020-10-13
IL251631B (en) 2020-05-31
US10106531B2 (en) 2018-10-23
SG11201702835RA (en) 2017-05-30
US12269814B2 (en) 2025-04-08
CN107001343A (zh) 2017-08-01
MX2017007188A (es) 2017-08-28
US20170037035A1 (en) 2017-02-09
CA2963625C (en) 2023-08-22
JP6666345B2 (ja) 2020-03-13
HUE048905T2 (hu) 2020-08-28
US20210048874A1 (en) 2021-02-18
US10662179B2 (en) 2020-05-26
JP2017536385A (ja) 2017-12-07
US20230295133A1 (en) 2023-09-21
BR112017008481A2 (pt) 2018-01-09
EP3227278A1 (en) 2017-10-11
HK1244795A1 (en) 2018-08-17
EP3227278B1 (en) 2020-02-05
WO2016087880A1 (en) 2016-06-09
AU2015356795B2 (en) 2020-01-16
CA2963625A1 (en) 2016-06-09
PT3227277T (pt) 2020-04-14
PL3227277T3 (pl) 2020-08-10
EA201791174A1 (ru) 2017-10-31
US10093659B2 (en) 2018-10-09
US20200031809A1 (en) 2020-01-30
EA033736B1 (ru) 2019-11-20
EP3227277A1 (en) 2017-10-11
CN112375073B (zh) 2024-04-16
JP2017536382A (ja) 2017-12-07
DK3227278T3 (da) 2020-04-27
HUE048685T2 (hu) 2020-07-28
US20190023696A1 (en) 2019-01-24
NZ730861A (en) 2021-04-30
KR102579848B1 (ko) 2023-09-18
US10344022B2 (en) 2019-07-09
ES2790875T3 (es) 2020-10-29
US20190276441A1 (en) 2019-09-12
AU2015356795A1 (en) 2017-04-27
US10450304B2 (en) 2019-10-22
ES2786374T3 (es) 2020-10-09
KR20170088850A (ko) 2017-08-02
US10858345B2 (en) 2020-12-08
US20210238169A1 (en) 2021-08-05
EP3227277B1 (en) 2020-02-05

Similar Documents

Publication Publication Date Title
ZA202004557B (en) Modulatory polynucleotides
IL277069B (en) Modified aminopurine compounds, their compositions and methods of treatment with them
MX370412B (es) Compuesto antimicotico.
MX2017016788A (es) Compuestos antibacterianos.
MX2017008444A (es) Picolinamidas como fungicidas.
NZ732799A (en) Picolinamides with fungicidal activity
PH12017500621A1 (en) Triazolopyrazinones as pde1 inhibitors
EP3102200A4 (en) Therapeutic compounds and compositions
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
IL248767B (en) Trimethoxyphenyl-benzaimidazole compounds for cancer treatment
PH12017500459A1 (en) Azetidinyloxyphenylpyrrolidine compounds
EP3397252A4 (en) COMPOSITIONS OF PERSONAL CARE
PL2998311T3 (pl) Mieszanina alkiloglikozydów, ich wytwarzanie i zastosowanie
MX379126B (es) Formulación de factor viii.
EP3169405A4 (en) Methods, compounds, and compositions for the treatment of musculoskeletal diseases
PH12016501495A1 (en) Hexahydrofuropyrroles as pde1 inhibitors
IL255167A0 (en) Compounds for the treatment of cancer
GB201513543D0 (en) Compositions for use in the treatment of diabetes
GB2546703A (en) Compounds
UA104671U (uk) Застосування яктону як нейропротектора
HK1232137B (en) Therapeutic compounds and compositions
UA92941U (uk) Застосування декаметоксину як протимікробного засобу проти бактерій роду bulkholderia
PH12014000104A1 (en) Therapeutic methods and compositions for treating diabetes
UA91508U (uk) Застосування пороху димного для лікування мікозів

Legal Events

Date Code Title Description
FG Grant or registration